Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Revenue (2016 - 2025)

Historic Revenue for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to $144000.0.

  • Perspective Therapeutics' Revenue fell 5200.0% to $144000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $836000.0, marking a year-over-year increase of 12198.26%. This contributed to the annual value of $1.4 million for FY2024, which is 195.26% down from last year.
  • Per Perspective Therapeutics' latest filing, its Revenue stood at $144000.0 for Q3 2025, which was down 5200.0% from $171000.0 recorded in Q2 2025.
  • Perspective Therapeutics' 5-year Revenue high stood at $2.9 million for Q1 2022, and its period low was -$4.9 million during Q4 2023.
  • Its 5-year average for Revenue is $1.2 million, with a median of $1.9 million in 2022.
  • Examining YoY changes over the last 5 years, Perspective Therapeutics' Revenue showed a top increase of 10626.27% in 2024 and a maximum decrease of 8627.0% in 2024.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Revenue stood at $2.8 million in 2021, then plummeted by 39.03% to $1.7 million in 2022, then plummeted by 385.5% to -$4.9 million in 2023, then skyrocketed by 106.26% to $307000.0 in 2024, then tumbled by 53.09% to $144000.0 in 2025.
  • Its Revenue stands at $144000.0 for Q3 2025, versus $171000.0 for Q2 2025 and $214000.0 for Q1 2025.